Polymorphisms of mouse apolipoprotein A-11: seven alleles found among 41 inbred strains of mice

References

• Barbaras R, Puchois P, Fruchart J C, Ailhaud G. Cholesterol efflux from cultured adipose cells is mediated by LpA‐I particles but not by LpA1:A‐II particles. Biochem Biophys Res Comm 1987; 142: 63–69
   PubMed Web of Science ®Google Scholar
• Matsunaga T, Hiasa Y, Yanagi H, Maeda T, Hattori N, Yamakawa K, Yamanouchi Y, Tanaka I, Obara T, Harnaguchi H. Apolipoprotein A‐I deficiency due to a codon 84 nonsense mutation of the apolipoprotein A‐I gene. Proc Natl Acad Sci USA 1991; 88: 2793–2797
   PubMedGoogle Scholar
• Pieters M N, Castro G G, Schouten D, Duchateau P, Fruchart J C, Van Berkel T J. Cholesterol esters selectively delivered in vivo by high‐density‐lipoprotein subclass LpA‐I to rat liver are processed faster into bile acids than are LpA‐I/A‐II‐derived cholesterol esters. Biochem J 1993; 292: 819–823
   PubMedGoogle Scholar
• Hedrick C C, Castellani L W, Warden C H, Puppione D L, Lusis A J. Influence of mouse apolipoprotein A‐II on plasma lipoproteins in transgenic mice. J Biol Chem 1993; 268: 20676–20682
   PubMedGoogle Scholar
• Mehrabian M, Qiao J H, Hyman R, Ruddle D, Laughton C, Lusis A J. Influence of the apoA‐II gene locus on HDL levels and fatty streak development in mice. Arterioscl Thromb 1993; 13: 1–10
   PubMedGoogle Scholar
• Schultz J R, Verstuyft J G, Gong E, Nichols A V, Rubin E M. Protein composition determines the anti‐atherogenic properties of HDL in transgenic mice. Nature 1993; 365: 762–764
   PubMed Web of Science ®Google Scholar
• Warden C H, Daluiski A, Bu X, Purcell‐Huynh D A, De Meester C, Shieh B H, Puppione D L, Gray R M, Reaven G M, Chen Y D, Rotter J I, Lusis A J. Evidence for link‐ of the apolipoprotein A‐II locus to plasma apolipoprotein A‐II and free fatty acid levels in mice and humans. Proc Natl AcadSci USA 1993; 90: 10886–10890
   PubMedGoogle Scholar
• Weng W, Breslow J L. Dramatically decreased high density lipoprotein cholesterol, increased remnant clearance, and insulin hypersensitivity in apolipoprotein A‐II knockout mice suggest a complex role for apolipoprotein A‐II in atherosclerosis susceptibility. Proc Natl AcadSci USA 1996; 93: 14788–14794
   PubMedGoogle Scholar
• Purcell‐Huynh D A, Weinreb A, Castellani L W, Mehrabian M, Doolittle M H, Lusis A J. Genetic factors in lipoprotein metabolism. Analysis of a genetic cross between inbred mouse strains NZB/BINJ and SM/J using a complete linkage map approach. J Clin Invest 1995; 96: 1845–1858
   PubMedGoogle Scholar
• Wang J, Kitagawa K, Kitado H, Kogishi K, Matsushita T, Hosokawa M, Higuchi K. Regulation of the metabolism of plasma lipoproteins by apolipoprotein A‐II. Biochim Biophys Acta 1997; 1345: 248–258
   PubMedGoogle Scholar
• Warden C H, Hedrick C C, Qiao J ‐H, Castellani L W, Lusis A J. Atherosclerosis in transgenic mice overexpressing apolipoprotein A‐II. Science 1993; 261: 469–472
   PubMedGoogle Scholar
• Yokoyama S. Apolipoprotein‐mediated cellular cholesterol efflux. Biochim Biophys Acta 1998; 1392: 1–15
   PubMed Web of Science ®Google Scholar
• Hamilton K K, Zhao J, Sims P J. Interaction between apolipoproteins A‐I and A‐II and the membrane attack complex of complement. Affinity of the apoproteins for polymeric C9. J Biol Chem 1993; 268: 3632–3638
   PubMedGoogle Scholar
• Handwerger S, Quarfordt S, Barrett J, Harman I. Apolipoproteins AI, AII, and CI stimulate placental lactogen release from human placental tissue. A novel action of high density lipoprotein apolipoproteins. J Clin Invest 1987; 79: 625–628
   PubMedGoogle Scholar
• Motizuki M, Itoh T, Satoh T, Yokota S, Yamada M, Shimamura S, Samejima T, Tsurugi K. Lipid‐binding and antimicrobial properties of synthetic peptides of bovine apolipoprotein A‐II. Biochem J 1999; 342: 215–221
   PubMedGoogle Scholar
• Sipe J D. Amyloidosis. Annu Rev Biochem 1992; 61: 947–975
   PubMed Web of Science ®Google Scholar
• Westermark P. The pathogenesis of amyloidosis. Understanding general principles. Am J Path 1998; 152: 1125–1127
   PubMed Web of Science ®Google Scholar
• Higuchi K, Yonezu T, Kogishi K, Matsumura A, Takeshita S, Kohno A, Matsushita M, Hosokawa M, Takeda T. Purification and characterization of a senile amyloid‐related antigenic substance (apoSASSAM) from mouse serum; apoSASSAM is an apoA‐II apolipoprotein of mouse high density lipoprotein. J Biol Chem 1986; 261: 12834–12840
   PubMed Web of Science ®Google Scholar
• Yonezu T, Higuchi K, Tsunasawa S, Takagi S, Sakiyama F, Takeda T. High homology is present in the primary structures between murine senile amyloid protein (ASSAM) and human apolipoprotein A‐II. FEBS Lett 1986; 203: 149–152
   PubMedGoogle Scholar
• Takeshita S, Hosokawa M, Irino M, Higuchi Shimizu K, Yasuhira K, Takeda T. Spontaneous age‐associated amyloidosis in Senescence‐Accelerated Mouse (SAM). Mech Ageing Dev 1982; 20: 13–23
   PubMed Web of Science ®Google Scholar
• Higuchi K, Matsumura A, Honma A, Takeshita S, Hashimoto K, Hosokawa M, Yasuhira K, Takeda T. Systemic senile amyloid in Senescence‐Accelerated Mice: A unique fibril protein demonstrated in tissues from various organs by the unlabeled immunoperoxidase method. Lab Invest 1983; 48: 231–240
   PubMedGoogle Scholar
• Higuchi K, Naiki H, Kitagawa K, Hosokawa M, Takeda T. Mouse senile amyloidosis: ASASM amyloidosis in mice presents universally as a systemic age‐associated amyloidosis. Virchows Arch B Cell Pathol 1991; 60: 231–239
   Google Scholar
• Chai C K. Spontaneous amyloidosis in LLC mice. Am J Pathol 1978; 90: 381–397
   PubMedGoogle Scholar
• Gruys E, Tooten P C, Kuijpers M H. Lung, ileum and heart are predilection sites for AApoAII amyloid deposition in CD‐1 Swiss mice used for toxicity studies. Pulmonary amyloid indicates AApoAII. Lab Anim 1996; 30: 28–34
   PubMedGoogle Scholar
• HogenEsch H, Niewold T A, Higuchi K, Tooten P C, Gruys E, Radl J. Gastrointestinal AAPOAII and systemic AA‐amyloidosis in aged C57BL/Ka mice. Amyloid‐type dependent effect of long‐term immunosuppressive treatment. Virchows Arch B Cell Pathol Incl Mol Pathol 1993; 64: 37–43
   PubMedGoogle Scholar
• Scheinberg M A, Cathcart E S, Eastcott J W, Skinner M, Benson M, Shirahama T. The SJL/J mouse: a new model for spontaneous age‐associated amyloidosis. I. Morphologic and immunochemical aspects. Lab Invest 1976; 35: 47–54
   PubMed Web of Science ®Google Scholar
• Shimizu K, Morita H, Niwa T, Maeda K, Shibata M, Higuchi K, Takeda T. Spontaneous amyloidosis in senile NSY mice. Acta Pathol Jpn 1993; 43: 215–221
   PubMedGoogle Scholar
• Staats J. Standardized nomenclature for inbred strains of mice: eighth listing. Cancer Res 1985; 45: 945–977
   PubMed Web of Science ®Google Scholar
• West W T, Murphy E D. Sequence of deposition of amyloid in strain A mice and relationship to renal disease. J Natl Cancer lnst 1965; 35: 167–174
   PubMedGoogle Scholar
• Higuchi K, Kitagawa K, Naiki H, Hanada K, Hosokawa M, Takeda T. Polymorphism of apolipoprotein A‐II (apoA‐II) among inbred strains of mice. Biochem J 1991; 279: 427–433
   PubMedGoogle Scholar
• Higuchi K, Hosokawa M, Takeda T. Senescence‐accelerated mouse. Methods Enzymol 1999; 309: 674–686
   PubMedGoogle Scholar
• Higuchi K, Naiki H, Kitagawa K, Kitado H, Kogishi K, Matsushita T, Takeda T. The apoA‐II gene and development of amyloidosis and senescence in a congenic strain of mice carrying amyloidogenic apoA‐II. Lab Invest 1995; 72: 7542
   Google Scholar
• Higuchi K, Wang J, Kitagawa K, Matsushita T, Kogishi K, Naiki H, Kitado H, Hosokawa M. Accelerated senile amyloidosis induced by amyloidogenic ApoA‐II gene shortens the life span of mice but does not accelerate the rate of senescence. J Gerontol A Biol Sci Med Sci 1996; 51: B295–302
   Google Scholar
• Naiki H, Higuchi K, Shimada A, Takeda T, Nakakuki K. Genetic analysis of murine senile amyloidosis. Lab Invest 1993; 68: 332–337
   PubMedGoogle Scholar
• Benson M D, Liepnieks J J, Yazaki M, Yamashita T, Hamidi As1 K, Guenther B, Kluve‐Beckerman B. A new human hereditary amyloidosis: the result of a stop‐codon mutation in the apolipoprotein AII gene. Genomics 2001; 72: 272–277
   PubMed Web of Science ®Google Scholar
• Doolittle D P, Davisson M T, Guidi J N, Green M C. Catalog of mutant genes and polymorphic loci. Genetic Variants and Strains of the Laboratory Mouse3rd ed, M F Lyon, S S Rasten, D M Brown. Oxford University Press, OxfordUK 1996; 17–854
   Google Scholar
• Higuchi K, Kogishi K, Wang J, Xia C, Chiba T, Matsuchita T, Hoshii Y, Kawano H, Ishihara T, Yokota T, Hosokawa M. Fibrilization in mouse senile amyloidosis is fibril conformation‐dependent. Lab Invest 1998; 78: 1535–1542
   PubMed Web of Science ®Google Scholar
• Xing Y, Nakamura A, Chiba T, Kogishi K, Matsushita T, Li F, Guo Z, Hosokawa M, Mori M, Higuchi K. Transmission of mouse senile amyloidosis. Lab Invest 2001; 81: 493–499
   PubMed Web of Science ®Google Scholar
• Ando Y, Tanaka Y, Ueyama H, Sakashita N, Yonehara T, Higuchi K, Araki S. Low plasma apolipoprotein AII levels in human and mouse amyloidosis with mutant transthyretin (Met‐30) gene. Ann Neurol 1993; 33: 101–103
   PubMedGoogle Scholar
• Xing Y, Higuchi K. Amyloid fibril proteins. Mech Ageing Dev 2002; 123: 1625–1636
   PubMed Web of Science ®Google Scholar
• Wang J, Matsushita T, Kogishi K, Xia C, Ohta A, Chiba T, Nakamura A, Kondo H, Mori M, Hosokawa M, Higuchi K. Wild type ApoA‐II gene does not rescue senescence‐accelerated mouse (SAMP1) from short life span and accelerated mortality. J Gerontol A Biol Sci Med Sci 2000; 55: B432–B439
   Google Scholar
• Guo Z, Toichi E, Hosono M, Hosokawa T, Hosokawa M, Higuchi K, Mori M. Genetic analysis of lifespan in hybrid progeny derived from the SAMP1 mouse strain with accelerated senescence. Mech Ageing Dev 2000; 118: 35–44
   PubMedGoogle Scholar
• Castellani L W, Goto A M, Lusisl A. Studies with apolipoprotein A‐II transgenic mice indicate a role for HDLs in adiposity and insulin resistance. Diabetes 2001; 50: 643–651
   PubMedGoogle Scholar
• Soto C, Sigurdsson E M, Morelli L, AsokKumar R, Casta$nTo E M, Frangione B. ß‐sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med 1998; 4: 822–826
   PubMed Web of Science ®Google Scholar
• Osherovich L Z, Weissman J S. Multiple Gln/Asnrich prion domains confer susceptibility to induction of the yeast [PSI(+)] prion. Cell 2001; 106: 183–194
   PubMed Web of Science ®Google Scholar
• Chiba T, Kogishi K, Wang J, Xia C, Matsushita T, Miyazaki J, Saito I, Hosokawa M, Higuchi K. Mouse senile amyloid deposition is suppressed by adenovirus‐mediated overexpression of amyloid‐resistant apolipoprotein A‐II. Am J Pathol 1999; 155: 1319–1326
   PubMedGoogle Scholar
• Chai C K, Lerner C. The inheritance of spontaneous amyloidosis development in mice: a model for hereditary threshold metabolic disorders. Am J Med Genet 1985; 22: 49–58
   PubMedGoogle Scholar
• Umezawa M, Tatematsu K, Korenaga T, Fu X, Matushita T, Okuyama H, Hosokawa M, Takeda T, Higuchi K. Dietary fat modulation of apoA‐II metabolism and prevention of senile amyloidosis in the senescence‐ accelerated mouse. J Lipid Res 2003; 44: 762–769
   PubMedGoogle Scholar
• Doolittle M H, LeBoeuf R C, Warden C H, Bee L M, Lusis A J. A polymorphism affecting apolipoprotein A‐II translational efficiency determines high density lipoprotein size and composition. J Biol Chem 1990; 265: 16380–16388
   PubMedGoogle Scholar
• Kitagawa K, Naiki H, Takeda T, Higuchi K. Age‐associated decreases in the messenger ribonucleic acid level and the rate of synthesis of apolipoprotein A‐II in murine senile amyloidosis. Lab Invest 1994; 70: 565–571
   PubMedGoogle Scholar